Compare iShares China Large-Cap ETF (FXI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Organon & Co. Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.69 (market cap $3.93B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares China Large-Cap ETF and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Organon & Co. Common Stock for 0 Days on average.
| FXI | OGN | |
|---|---|---|
Market Cap | $3.93B | $3.62B |
Volume | 14,707,409 | 2,892,999 |
52-Week High | $41.08 | $13.81 |
52-Week Low | $31.59 | $5.70 |
Typical Hold Time | 151 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $34.17 with minimal daily movement (+0.09%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong corporate profit growth but concerns over industrial overcapacity and trade tensions. The ETF offers value exposure with a P/E ratio approximately half that of the S&P 500, but faces significant geopolitical and economic headwinds.
The outlook for FXI remains clouded by US-China relations and domestic economic challenges. Investment opportunity lies in its valuation discount versus US equities and potential policy support from Chinese authorities. Key risks include escalating trade protectionism, weak domestic consumption, and regulatory uncertainty. Analyst sentiment is divided, reflecting the high-risk, high-reward nature of Chinese large-cap exposure.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
